1. 106519029 一种Aβ寡聚体抗体的制备工艺
CN
22.03.2017
C07K 16/18 Loading...
C07K 16/18
Loading...
102016000930548
山东泰邦生物制品有限公司
宋佃卫
C07K 16/18
Loading...
本发明公开了一种Aβ寡聚体抗体的制备工艺，制备工艺包括以下步骤：调整上层析柱前样品的电导、pH和蛋白浓度；亲和凝胶层析；将亲和层析柱下来的洗脱液过滤，超滤，配制；病毒灭活，无菌分装。该工艺采用一步亲和层析，提纯倍数为85‑100倍，纯化获得的Aβ寡聚体抗体浓度高、靶向性明确，具有广阔的临床应用前景。
2. 106520889 一种3α‑羟基‑7氧代‑5β‑胆烷酸的制备方法及其制备用酶3
CN
22.03.2017
C12P 33/02 Loading...
C12P 33/02
Loading...
201710012411.6
眉山市新功生物科技有限公司
傅荣昭
C12P 33/02
Loading...
本发明涉及一种利用生物酶催化技术制备3α‑羟基‑7氧代‑5β‑胆烷酸的方法及其制备用7α‑类固醇脱氢酶。该方法以鹅去氧胆酸为底物，在NAD、乳酸脱氢酶、丙酮酸钠以及缓冲溶液存在的条件下，用7α‑类固醇脱氢酶催化鹅去氧胆酸制备3α‑羟基‑7氧代‑5β胆烷酸，其中7α‑类固醇脱氢酶来源于Brevundimonas naejangsanensis。该方法操作简单、反应条件温和易控、反应时间短、对底物的转化率高达99.8%以上，所获得的产品的含量在96.8%以上。
3. 106501524 一种静注人免疫球蛋白Fc段活性检测方法
CN
15.03.2017
G01N 33/68 Loading...
G01N 33/68
Loading...
102016000856621
山东泰邦生物制品有限公司
陈晨
G01N 33/68
Loading...
本发明公开了一种静注人免疫球蛋白Fc段活性检测方法，采用更易获得的稳定抗原，添加系统适用性验证，采用细胞计数法直观的检测红细胞溶血，降低传统OD值间接检测时样本澄明度、杂蛋白、试剂、设备耗材等造成的结果波动，提高检测结果的精密度。同时缩小检测体系、提高通量，操作更为便捷。
4. 106492240 一种冻干机在线清洗及灭菌系统及方法
CN
15.03.2017
A61L 2/07 Loading...
A61L 2/07
Loading...
102016000834112
山东泰邦生物制品有限公司
周安
A61L 2/07
Loading...
本发明提供一种冻干机在线清洗及灭菌系统，包括：控制器，冻干箱，冷凝箱，冻干箱入口和冷凝箱入口分别连接入口管道，入口管道的进口组设有进口总阀门，蒸汽口上设有蒸汽阀门，水进口上设有进水阀门，空气进口上设有空气阀门，压缩空气进口上设有压缩空气阀门；冻干箱设有冻干箱排水排气口，冻干箱排水排气口上设有第一排水排气阀门；冷凝箱设有冷凝箱排水排气口，冷凝箱排水排气口上设有第二排水排气阀门；冻干箱排水排气口和冷凝箱排水排气口分别连接排水排气管道；系统采用该清洗及灭菌方法，可以实现冻干机在线清洗及在线灭菌，并且实现比现有技术中更短的降温时间，实现了生产的便利性。实现节能降耗的目的。
5. 106470687 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的保健品中的应用及其保健品
CN
01.03.2017
A61K 31/706 Loading...
A61K 31/706
Loading...
112015000030067
邦泰生物工程（深圳）有限公司
傅荣昭
A61K 31/706
Loading...
一种以烟酰胺单核苷酸为活性成分的保健品，以及烟酰胺单核苷酸在制备用于预防和治疗动脉硬化和动脉硬化引起的心脑血管疾病的保健品中的应用。
6. 2017504616 β−ニコチンアミドモノヌクレオチドの精製方法
JP
09.02.2017
C12P 19/30 Loading...
C12P 19/30
Loading...
2016542666
邦泰生物工程（深▲セン▼）有限公司
傅栄昭
C12P 19/30
Loading...
本発明は、前処理されたβ-ニコチンアミドモノヌクレオチド溶液に膜濃縮装置で精密濾過及びナノ濾過を順次行い、濃縮された粗溶液を収集するステップaと、得られた粗溶液のpH値を3〜7に調整し、サンプルを逆相高速液体クロマトグラフ分取カラムに注入し、固定相がオクタデシルシラン結合シリカゲルであり、移動相Aが塩酸溶液で調製されたpH3〜7の溶液であり、移動相Bがエタノールである条件で、勾配溶離による精製を行い、精製されたサンプル溶液を得るステップbと、精製されたサンプル溶液を膜濃縮装置でナノ濾過した後、真空凍結乾燥機で凍結乾燥し、精製されたβ-ニコチンアミドモノヌクレオチドを得るステップcと、を含むβ-ニコチンアミドモノヌクレオチドの精製方法を開示する。
7. 104109202 一种从血浆中吸附人凝血酶原复合物的方法
CN
01.02.2017
C07K 14/745 Loading...
C07K 14/745
Loading...
102014000340403
山东泰邦生物制品有限公司
马山
C07K 14/745
Loading...
本发明涉及一种采用固定床柱层析技术从血浆中吸附人凝血酶原复合物的生产方法，包括以下步骤：（1）去除冷沉淀血浆，使用预先经EDTA溶液和枸橼酸钠溶液清洗过的纤维素深层滤板过滤（2）深层过滤后的血浆在固定床上样时经过0.2μm的滤芯膜在线过滤；（3）装填有阴离子交换凝胶Capto DEAE的固定床层析柱使用缓冲液A平衡2~5个柱体积，血浆上样流速为60~120cm/h，用缓冲液B洗涤层析柱，用缓冲液C洗脱层析柱，得到PCC制品，按照凝血因子IX计算，PCC的收率可以达到75%~90%，比活性可以达到5.5IU/mg以上。
8. 103893135 一种人血浆蛋白C的冻干稳定剂组合物及其用途
CN
11.01.2017
A61K 9/19 Loading...
A61K 9/19
Loading...
102014000122754
中国医学科学院输血研究所
王宗奎
A61K 9/19
Loading...
本发明公开了一种人血浆蛋白C的冻干稳定剂组合物，它是乳糖、甘露醇、海藻糖、组氨酸、精氨酸、酪氨酸、天冬氨酸以及它们的盐中的任意一种或者任意两种以上的组合。本发明稳定剂可以有效保护蛋白C，制得的蛋白C制剂的外观成型好，蛋白Ｃ活性损失小，回收率高，具有良好的临床应用前景。
9. 104402993 一种制备静注人免疫球蛋白的方法
CN
04.01.2017
C07K 16/06 Loading...
C07K 16/06
Loading...
102014000709955
贵州泰邦生物制品有限公司
陈云华
C07K 16/06
Loading...
本发明提供了一种制备静注人免疫球蛋白的方法，它包括如下步骤：a、溶解：取Cohn法F Ⅱ沉淀，溶于注射用水中，澄清过滤，调节pH为6.60±0.1，搅匀，调节电导率为1.40±0.05ms/cm，调节温度为0～5℃，搅匀；b、层析：用DEAE Sepharose Fast Flow的层析柱纯化，收集人免疫球蛋白组份液；c、超滤：将步骤b的流穿液超滤并透析，至渗透压低于30mOsmol/kg时，浓缩，浓缩至蛋白浓度4.0％±1％(w/v)，得浓缩液；d、病毒灭活：在浓缩液中添加山梨醇至浓度为(33±1)％(w/v)，调整pH至5.00±0.1，在60℃±0.5℃下恒温10小时，冷却，澄清过滤；e、超滤，透析，配制，即可。本发明方法制备的静注人免疫球蛋白纯度高，Fc段生物学活性高，品质好，IgA等杂质因子含量低，副作用小，得率高，具有良好的市场应用前景。
10. WO/2016/188091 USE OF NICOTINAMIDE MONONUCLEOTIDE IN PREPARING MEDICATIONS FOR PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND CARDIOVASCULAR AND CEREBROVASCULAR DISEASES, AND MEDICATION THEREOF
WO
01.12.2016
A61K 31/706 Loading...
A61K 31/706
Loading...
PCT/CN2015/097072
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
A61K 31/706
Loading...
A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.
11. WO/2016/188092 USE OF NICOTINAMIDE MONONUCLEOTIDE IN PREPARING HEALTH CARE PRODUCTS FOR PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND CARDIOVASCULAR AND CEREBROVASCULAR DISEASES, AND HEALTH CARE PRODUCT THEREOF
WO
01.12.2016
A61K 31/706 Loading...
A61K 31/706
Loading...
PCT/CN2015/097073
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
A61K 31/706
Loading...
A health care product having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing health care products for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.
12. WO/2016/169307 CREATINE KINASE MUTATION, GENE AND USE OF MUTATION
WO
27.10.2016
C12N 9/12 Loading...
C12N 9/12
Loading...
PCT/CN2016/070724
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
C12N 9/12
Loading...
A creatine kinase mutation, gene and use of the mutation. The mutation takes attached sequence 2 as a reference sequence, has at least one mutation selected from the 100th site, the 121st site and the 33rd site, takes creatine and adenosine triphosphate (ATP) as substrates and has a creatine kinase catalytic activity at least 50% higher than a parent. The creatine kinase mutation can be used to produce phosphocreatine.
13. 105532641 一种胎盘保存液及其使用方法
CN
28.09.2016
A01N 1/02 Loading...
A01N 1/02
Loading...
102015000995653
贵州泰邦生物制品有限公司
杨刚
A01N 1/02
Loading...
本发明涉及一种保存采集后的胎盘保存液及其使用方法，属于生物技术领域。一种胎盘保存液，由海藻糖、醋酸酯淀粉、卵磷脂、乙烯乙二醇、聚乙烯吡咯烷酮、柠檬酸、柠檬酸三钠、聚山梨酯组成。本发明胎盘保存液，能够深入胎盘内部结构，具有降低冰点，减少冰晶形成、平衡细胞内外渗透压、减轻细胞缩水程度、避免多肽失活等作用。本发明胎盘保存液配比简单，使用方便，能大幅度减少多肽等活性物质在冷冻过程中的损害。
14. WO/2016/145910 APPLICATION OF NADH AND NMN IN PREPARATION OF PARKINSON'S DISEASE DRUG OR HEALTH CARE PRODUCT
WO
22.09.2016
A61K 31/7084 Loading...
A61K 31/7084
Loading...
PCT/CN2015/096288
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
A61K 31/7084
Loading...
An application of nicotinamide adenine dinucleotide (NADH) and nicotinamide mononucleotide (NMN) in the preparation of a drug or health care product treating Parkinson's disease, β-NADH and β-NMN being prepared via enzyme catalysis.
15. WO/2016/145911 APPLICATION OF NICOTINAMIDE MONONUCLEOTIDE IN PREPARATION OF ANTI-AGING DRUG OR HEALTH CARE PRODUCT
WO
22.09.2016
A61K 31/706 Loading...
A61K 31/706
Loading...
PCT/CN2015/096334
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
A61K 31/706
Loading...
An application of nicotinamide mononucleotide in the preparation of an anti-aging drug or health care product, a single dose of nicotinamide mononucleotide being 1-500mg/kilogram of body weight/day, the drug or health care product being a tablet, a capsule, granules, an aqueous solution, an enteric preparation or an injection.
16. WO/2016/145912 NICOTINAMIDE MONONUCLEOTIDE-CONTAINING ANTI-AGING BEAUTY AND SKIN CARE PRODUCT COMPOSITION
WO
22.09.2016
A61K 8/60 Loading...
A61K 8/60
Loading...
PCT/CN2015/096351
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
A61K 8/60
Loading...
A nicotinamide mononucleotide-containing anti-aging beauty and skin care product composition, nicotinamide mononucleotide being used as an active ingredient for application in the anti-aging beauty and skin care product composition.
17. WO/2016/101782 METHOD FOR PURIFYING OXIDIZED Β-NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE
WO
30.06.2016
C07H 19/207 Loading...
C07H 19/207
Loading...
PCT/CN2015/096408
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
C07H 19/207
Loading...
An oxidized β-nicotinamide adenine dinucleotide phosphate and a purification method therefor, specifically comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a pre-treated nicotinamide adenine dinucleotide phosphate solution and obtaining a concentrated crude solution; b. adjusting the pH value of the obtained crude solution to be from 2 to 4, injecting sample and applying a preparation column for reversed-phase high performance liquid chromatography, and performing purification by gradient elution to obtain a purified sample solution; c. using the membrane concentration equipment to perform nanofiltration on the purified sample solution, using a vacuum freeze dryer to perform lyophilization, and obtaining purified nicotinamide adenine dinucleotide phosphate. The nicotinamide adenine dinucleotide phosphate prepared using the present invention has high purity, high yield, and good market prospect.
18. 103910790 一种制备人血浆蛋白C浓缩物的方法
CN
29.06.2016
C07K 14/47 Loading...
C07K 14/47
Loading...
102014000122447
贵州泰邦生物制品有限公司
王玉梅
C07K 14/47
Loading...
本发明公开了一种制备人血浆蛋白C浓缩物的方法，它包括如下步骤：（1）凝胶吸附：取凝胶，充分溶胀，用平衡液平衡，加入去冷沉淀血浆，加入量为凝胶的250～750倍（v/w），搅拌吸附，去上清，洗涤，洗脱，得洗脱液；（2）超滤，透析：将洗脱液超滤，得浓缩液，再透析至电导率低于10mS/cm；（3）S/D灭活；（4）肝素亲和层析：用缓冲液平衡肝素亲和层析柱，上样，用氯化钠浓度为0.01～0.1M的缓冲液洗涤，再用氯化钠浓度为0.1～0.18M的缓冲液洗脱，得洗脱液；（5）超滤，透析，无菌分装，冻干，干热病毒灭活，即可。本发明制备方法简单，成本低，得率很高，制得的产品纯度高，活性强，工业应用前景良好。
19. WO/2016/091119 METHOD FOR PURIFYING OXIDIZED Β-NICOTINAMIDE ADENINE DINUCLEOTIDE
WO
16.06.2016
C07H 19/207 Loading...
C07H 19/207
Loading...
PCT/CN2015/096378
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
C07H 19/207
Loading...
Disclosed is a method for purifying oxidized β-nicotinamide adenine dinucleotide, comprising the steps: using a filter membrane to perform microfiltration and nanofiltration on a reaction liquid obtained from an enzyme catalysis reaction, and collecting the concentrated solution for further use; adding an acid to the concentrated filtrate so as to adjust the pH value of the concentrated solution, and performing purification by means of gradient elution using a reversed-phase chromatographic column as the stationary phase, a buffer salt solution as phase A, and ethanol as phase B; using a filter membrane to perform nanofiltration and concentration on the purified solution, and then using a vacuum freeze dryer to perform lyophilization. The present invention uses reversed-phase high performance liquid chromatography to purify oxidized β-nicotinamide adenine dinucleotide, resulting in highly pure oxidized β-nicotinamide adenine dinucleotide with good yield that meets the industrialization requirements.
20. WO/2016/091121 METHOD FOR PURIFYING REDUCED Β-NICOTINAMIDE ADENINE DINUCLEOTIDE
WO
16.06.2016
C07H 19/207 Loading...
C07H 19/207
Loading...
PCT/CN2015/096403
BONTAC BIO-ENGINEERING (SHENZHEN) CO.,LTD
FU, Rongzhao
C07H 19/207
Loading...
Disclosed is a method for purifying reduced β-nicotinamide adenine dinucleotide, comprising the steps: performing microfiltration and then nanofiltration on a reaction liquid obtained from an enzyme catalysis reaction, and collecting the concentrated solution for further use; adding an ion pair reagent to the concentrated solution, and performing purification by means of gradient elution using a reversed-phase chromatographic column as the stationary phase, a buffer salt solution as phase A, and ethanol as phase B; using cation exchange resin to convert the cations in the purified filtrate into sodium ions; performing nanofiltration on the filtrate obtained from the steps above, and finally using a vacuum freeze dryer to perform lyophilization. The present invention uses reversed-phase high performance liquid chromatography and cation exchange to purify reduced β-nicotinamide adenine dinucleotide, resulting in highly pure reduced β-nicotinamide adenine dinucleotide with good yield that meets industrialization requirements.
21. 105671096 一种通过生物催化生产磷酸肌酸的方法
CN
15.06.2016
C12P 13/00 Loading...
C12P 13/00
Loading...
201610128871.0
邦泰生物工程(深圳)有限公司
傅荣昭
C12P 13/00
Loading...
一种通过生物催化生产磷酸肌酸的方法，涉及磷酸肌酸的制备方法的技术领域。本发明提供的方法主要解决磷酸肌酸现有的生物催化生产方法产率低、成本高的技术问题，该方法具体为以肌酸和三磷酸腺苷为底物，在肌酸激酶突变体的催化作用下生产磷酸肌酸，所述肌酸激酶突变体具有如SEQ？ID？NO：3所示的氨基酸序列，该氨基酸序列的特点是将肌酸激酶亲本的氨基酸序列中第33位点的Val突变为Ala。该肌酸激酶突变体的比活性较肌酸激酶亲本高出80%，该方法使肌酸转化为磷酸肌酸的转化率超过85%，适于大规模工业化生产。
22. WO/2016/086860 PURIFICATION METHOD FOR Β-NICOTINAMIDE MONONUCLEOTIDE
WO
09.06.2016
C07H 1/06 Loading...
C07H 1/06
Loading...
PCT/CN2015/096215
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
C07H 1/06
Loading...
Disclosed is a purification method for β-nicotinamide mononucleotide, comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a pre-treated β-nicotinamide mononucleotide solution and collecting a concentrated crude solution; b. adjusting the pH value of the obtained crude solution to be from 3 to 7, injecting sample and applying a preparation column for reversed-phase high performance liquid chromatography, the stationary phase being octadecylsilane bonded silica, the mobile phase A being a solution having the pH value from 3 to 7 formulated using a hydrochloride solution, the mobile phase B being ethanol, and performing purification by gradient elution to obtain a purified sample solution; c. using the membrane concentration equipment to perform nanofiltration on the purified sample solution, using a vacuum freeze dryer to perform lyophilization, and obtaining purified β-nicotinamide mononucleotide.
23. 105647986 生物催化生产磷酸肌酸的方法
CN
08.06.2016
C12P 13/00 Loading...
C12P 13/00
Loading...
201610129959.4
邦泰生物工程（深圳）有限公司
傅荣昭
C12P 13/00
Loading...
生物催化生产磷酸肌酸的方法，涉及磷酸肌酸的制备方法的技术领域。本发明提供的方法主要解决磷酸肌酸现有的生物催化生产方法产率低、成本高的技术问题，该方法具体为以肌酸和三磷酸腺苷为底物，在肌酸激酶突变体的催化作用下生产磷酸肌酸，所述肌酸激酶突变体具有如SEQ？ID？NO：3所示的氨基酸序列，该氨基酸序列的特点是将肌酸激酶亲本的氨基酸序列中第100位点的Phe突变为Tyr。该肌酸激酶突变体的比活性较肌酸激酶亲本高出111%，该方法使肌酸转化为磷酸肌酸的转化率超过85%，适于大规模工业化生产。
24. 105647985 一种生物催化生产磷酸肌酸的方法
CN
08.06.2016
C12P 13/00 Loading...
C12P 13/00
Loading...
201610128655.6
邦泰生物工程（深圳）有限公司
傅荣昭
C12P 13/00
Loading...
一种生物催化生产磷酸肌酸的方法，涉及磷酸肌酸的制备方法的技术领域。本发明提供的方法主要解决磷酸肌酸现有的生物催化生产方法产率低、成本高的技术问题，该方法具体为以肌酸和三磷酸腺苷为底物，在肌酸激酶突变体的催化作用下生产磷酸肌酸，所述肌酸激酶突变体具有如SEQ？ID？NO：3所示的氨基酸序列，该氨基酸序列的特点是将肌酸激酶亲本的氨基酸序列中第121位点的Leu突变为Asp。该肌酸激酶突变体的比活性较肌酸激酶亲本高出52%，该方法使肌酸转化为磷酸肌酸的转化率超过85%，适于大规模工业化生产。
25. WO/2016/074641 USE OF NADH OR SALT THEREOF IN PREPARING DRUG OR HEALTH CARE PRODUCT FOR PHENYLKETONURIA TREATMENT
WO
19.05.2016
A61K 31/7076 Loading...
A61K 31/7076
Loading...
PCT/CN2015/094502
BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD
FU, Rongzhao
A61K 31/7076
Loading...
Use of reduced nicotinamide adenine dinucleotide (NADH) or salt thereof in preparing a drug or health care product for phenylketonuria treatment, a single dose of the NADH or salt thereof being 1-100 mg.
26. 205241656 一种无菌连接器及连接组件
CN
18.05.2016
C12M 1/00 Loading...
C12M 1/00
Loading...
201521034243.3
山东泰邦生物制品有限公司
李杰
C12M 1/00
Loading...
本实用新型属于生物制药设备技术领域，具体地涉及一种无菌连接器及连接组件，包括连接头，所述连接头包括连接管一和连接管二，所述连接管二的一端设有快接面A，连接管二的另一端设有快接面B，所述快接面B连接有保护套，所述保护套位于连接管一的外部，所述保护套与连接管一之间形成有灭菌空腔。本实用新型具有可以保证移动罐和外围附加设施的无菌特性的优点。
27. 105535009 一种预防和治疗听力损失的药物或保健品
CN
04.05.2016
A61K 31/706 Loading...
A61K 31/706
Loading...
201610055028.4
邦泰生物工程（深圳）有限公司
傅荣昭
A61K 31/706
Loading...
一种预防和治疗听力损失的药物或保健品，涉及生物医药和保健品技术领域。针对目前市场上用于治疗听力损失的药物不多且效果欠佳以及缺乏相应的保健品的缺陷，本发明旨在开发一种有效且针对性强的用于预防和治疗听力损失的药物以及相应的保健品，特别是对包括年龄相关性听力损失、噪声性听力损失以及突发性听力损失等在内的感音神经性听力损失有特效的药物以及相应的保健品，其特征在于：所述药物或保健品中含有活性成分烟酰胺单核苷酸。该药物或保健品具有起效快、疗效高、功效稳定、对人体无毒副作用等优点。
28. 105532641 一种胎盘保存液及其使用方法
CN
04.05.2016
A01N 1/02 Loading...
A01N 1/02
Loading...
201510995653.2
贵州泰邦生物制品有限公司
杨刚
A01N 1/02
Loading...
本发明涉及一种保存采集后的胎盘保存液及其使用方法，属于生物技术领域。一种胎盘保存液，由海藻糖、醋酸酯淀粉、卵磷脂、乙烯乙二醇、聚乙烯吡咯烷酮、柠檬酸、柠檬酸三钠、聚山梨酯组成。本发明胎盘保存液，能够深入胎盘内部结构，具有降低冰点，减少冰晶形成、平衡细胞内外渗透压、减轻细胞缩水程度、避免多肽失活等作用。本发明胎盘保存液配比简单，使用方便，能大幅度减少多肽等活性物质在冷冻过程中的损害。
29. 105456286 烟酰胺单核苷酸在制备用于防治听力损失的药物或保健品中的应用
CN
06.04.2016
A61K 31/706 Loading...
A61K 31/706
Loading...
201610061851.6
邦泰生物工程（深圳）有限公司
傅荣昭
A61K 31/706
Loading...
烟酰胺单核苷酸在制备用于防治听力损失的药物或保健品中的应用，涉及烟酰胺单核苷酸的用途技术领域。本发明旨在解决至今尚无有效且针对性强的用于预防和治疗听力损失的药物或保健品的技术问题，提供了一种烟酰胺单核苷酸的新用途，具体是指烟酰胺单核苷酸在制备用于预防和治疗听力损失的药物或保健品中的应用。经临床试验证实：感音神经性听力损失的患者口服烟酰胺单核苷酸后的治愈率达60.3%，总有效率高达91.4%。
30. 105420325 一种胎盘多肽的制备方法
CN
23.03.2016
C12P 21/06 Loading...
C12P 21/06
Loading...
201510995668.9
贵州泰邦生物制品有限公司
杨刚
C12P 21/06
Loading...
本发明涉及一种生物活性物质的制备方法，具体为一种胎盘多肽的制备方法。一种胎盘多肽的制备方法，是将胎盘剪碎后加入生理盐水进行组织匀浆，然后将所得产品与蛋白酶混合进行酶解反应，离心并收集离心液，通过反胶团萃取制得胎盘多肽、蛋白酶粗提液，粗提液进行超滤，收集超滤液，干燥制得胎盘多肽。本发明制备方法简单，生产成本低、设备投入少，易于大规模生产。
31. 105037487 一种人血白蛋白的制备方法
CN
11.11.2015
C07K 1/34 Loading...
C07K 1/34
Loading...
201510491743.8
山东泰邦生物制品有限公司
井金荣
C07K 1/34
Loading...
本发明涉及生物制品和血液制品生产的技术领域，主要涉及血液制品生产中人血白蛋白的分离纯化方法，具体为一种人血白蛋白的制备方法。以健康人血浆上清为原料，采用Kistler‑Nitchmann低温乙醇法沉淀、分离组分FI+II+III和组分FIV，对组分FIV分离后上清液进行脱醇处理后，再配合一步离子交换层析，超滤，加入适量的辛酸钠作为稳定剂，经巴氏病毒灭活处理后得到人血白蛋白成品。经高效液相色谱法检测该工艺制备的人血白蛋白的纯度≥99％，多聚体含量≤1％，收率达到28~30g/L血浆。制品的纯度更高，杂蛋白含量更低，使得临床用药更加安全。
32. 104959353 一种节水降温型的在线清洗方法
CN
07.10.2015
B08B 9/032 Loading...
B08B 9/032
Loading...
201510393024.2
山东泰邦生物制品有限公司
李斌
B08B 9/032
Loading...
本发明属于用于生物制药领域的在线清洗方法，用于生物制药领域的反应罐和管路的清洁降温，具体涉及一种节水降温型的在线清洗方法，为反应罐及管路的全自动在线清洗方法。包括如下步骤：1清洗前确认符合清洗条件；2纯化水清洗；3压缩空气吹扫；4碱液清洗；5压缩空气吹扫；6注射用水清洗；7低温压缩空气吹扫；9结束。克服了现有在线清洗方法的不足，在确保清洗效果的基础上，不仅缩短了清洗后的降温时间，同时可以达到了节能降耗，节约用水的目的。
33. 104360055 测定水痘-带状疱疹病毒中和抗体的试剂盒及生产使用方法
CN
18.02.2015
G01N 33/543 Loading...
G01N 33/543
Loading...
201410621724.8
山东泰邦生物制品有限公司
朱孟沼
G01N 33/543
Loading...
本发明涉及体外诊断试剂的技术领域，具体是一种能测定水痘-带状疱疹病毒中和抗体效价的试剂盒及其生产方法。该试剂盒采用感染VZV的细胞作为抗原，包被固定在96孔板的孔内，使用细胞表面携带的大量病毒糖蛋白（中和抗原）来捕获待测样品中的中和抗体，同时保持细胞完整，内部的其他病毒抗原并不与样品接触，从而能保证测定中和抗体的特异性。该试剂盒可以直接用于自动生化分析仪或酶标仪，快速测定VZV中和抗体效价。测定过程简单、快捷，测定样本通量高，并能实现定量测定。
34. 104352513 Application of NADH (reduced form of nicotinamide-adenine dinucleotid) or salt thereof in preparing medicament or healthcare product for treating phenylketonuria
CN
18.02.2015
A61K 31/7076 Loading...
A61K 31/7076
Loading...
201410644152.5
邦泰生物工程(深圳)有限公司
傅荣昭
A61K 31/7076
Loading...
The invention discloses an application of NADH (reduced form of nicotinamide-adenine dinucleotid) or a salt thereof in preparing a medicament or a healthcare product for treating phenylketonuria. Nicotinamide adenine dinucleotide or a salt thereof is used as an active ingredient applied to the medicament or the healthcare product for treating phenylketonuria. The specific dosage of the NADH or salt thereof can be determined according to the severity of the pathogenetic condition, a medicament application way and an associated factor. After a patient with phenylketonuria takes the medicament or the healthcare product containing the NADH, the phenylketonuria is obviously improved. Moreover, the dear low-phenylalanine diet is obviously reduced, the common food is increased, and the cost is greatly lowered.
35. 104328092 Glutathione synthetase mutant, encoding gene and application
CN
04.02.2015
C12N 9/00 Loading...
C12N 9/00
Loading...
201410506648.6
邦泰生物工程（深圳）有限公司
傅荣昭
C12N 9/00
Loading...
The invention discloses a glutathione synthetase mutant, an encoding gene and an application. The glutathione synthetase mutant is obtained through point mutation of the sequence 2 in a sequence table, wherein the point mutation is at least one mutation at the 128th position, the 256th position and the 320th position. By means of mutation of the glutathione synthetase gene sequence, the glutathione synthetase mutant having high catalytic activity is finally obtained and is higher than a parent by at least 50% in glutathione synthetase catalytic activity with disodium adenosine triphosphate, L-sodium glutamate, L-cysteine and glycine being a substrate. When immobilized glutathione synthetase is employed for preparing glutathione, the concentration of the prepared glutathione is higher than 50 mM, so that the glutathione synthetase mutant is available in industrialized production of the glutathione with production cost being reduced and market competitiveness of related products being enhanced.
36. 204073564 一种改进型批式吸附凝胶过滤装置
CN
07.01.2015
B01D 29/085 Loading...
B01D 29/085
Loading...
201420381291.9
山东泰邦生物制品有限公司
朱孟沼
B01D 29/085
Loading...
本实用新型公开了一种改进型批式吸附凝胶过滤装置，包括密闭式过滤柱、支撑旋转装置，所述过滤柱内部设置有滤布和筛板，本实用新型设计了滤布的固定方式，能在滤布表面形成切向流的喷料嘴、柱体侧部设置了排气及凝胶卸料口以及能使过滤柱做摇篮式摆动的电机。本实用新型可以实现切向流过滤，进一步缩短凝胶过滤所需的时间，提高效率；可以实现凝胶的无搅拌混匀，减少凝胶破损；可以实现有效的滤布固定和柱体密封，防止泄露凝胶和料液泄露；可以实现凝胶卸料和排气功能，方便操作。
37. 103869057 Needle biopsy tissue chip
CN
18.06.2014
G01N 33/48 Loading...
G01N 33/48
Loading...
201210538814.1
泰州医药城博奥邦科生物科技有限公司
郜恒骏
G01N 33/48
Loading...
The invention provides a technology and method for preparing high throughput needle biopsy tissue chip. The method comprises the following steps: collecting 42 residual paraffin-embedded tissue samples of needle biopsy of patients who have been diagnosed as the breast cancer patients through pathological examination on mammary gland needle biopsy tissues; taking the corresponding normal pathological HE stained sections as the guide, cutting the paraffin-embedded tissue sections (1mm to 4mm) corresponding to the cancer parts of the HE-stained sections, preparing paraffin-embedded tissue cores, preparing breast cancer needle biopsy tissue arrays by utilizing a tissue chip instrument, cutting paraffin into slices, and preparing paraffin-embedded tissue chip of breast cancer needle biopsy tissue. The prepared needle biopsy tissue chip can be applied to molecular medical research of related diseases such as immunocytochemistry, in-situ hybridization, and the like.
38. 103613662 Method for separating and purifying human antithrombin-III from human plasma
CN
05.03.2014
C07K 14/81 Loading...
C07K 14/81
Loading...
201310604723.8
INSTITUTE OF BLOOD TRANSFUSION, CHINESE ACADEMY OF MEDICAL SCIENCES
WANG ZONGKUI
C07K 14/81
Loading...
The invention discloses a method for separating and purifying human antithrombin-III from human cryoprecipitate-reduced plasma. The method comprises the operating steps of performing chromatography on the human cryoprecipitate-reduced plasma, performing S/D (solvent/detergent) virus inactivation, and performing affinity chromatography for the second time; performing ultrafiltration; performing sterilizing filtration; filtering with a 20nm nano-filtration membrane to remove viruses; subpackaging; performing freeze-drying; performing dry heat virus inactivation; separating and purifying human antithrombin-III from the human cryoprecipitate-reduced plasma; performing pre-filtration treatment, and then directly separating and purifying antithrombin-III (AT-III) out of the plasma by adopting an affinity chromatography technology; adding an appropriate amount of a protective agent, replacing pasteurella virus inactivation process with an S/D virus inactivation process to reduce the loss and activity and shorten the preparation time; then performing affinity chromatography for the second time to further purify the AT-III, and finally performing the steps of ultrafiltration, virus removal through nano-filtration with a 20nm nano-membrane, freeze-drying and the like, wherein the purity of the final product is more than 95%, the specific activity is more than 6IU/mg, the virus safety is high, and blood plasma can not be influenced during preparation to produce a downstream product.
39. 203060887 一种凝胶批式吸附装置
CN
17.07.2013
B01D 15/00 Loading...
B01D 15/00
Loading...
201320077631.4
山东泰邦生物制品有限公司
高建锋
B01D 15/00
Loading...
本实用新型公开了一种凝胶批式吸附装置，用于生物制药、食品及化工等领域，包含有密闭式的吸附柱（1），所述吸附柱（1）内部设置有凝胶储存装置（2），凝胶储存装置（2）与设置在吸附柱（1）侧壁的第一转轴（6）和第二转轴（7）相连，第一转轴（6）与外部的变频器（8）及马达（9）相连，所述凝胶储存装置（2）表面固定有搅拌桨（3）。本实用新型设置为密闭的吸附装置，更符合制药及食品等应用领域严格的质量要求；凝胶固定在凝胶储存装置内，提高了凝胶寿命，降低了生产成本；不需要对吸附后的料液进行凝胶过滤，缩短了工艺时间，提高了产品质量。
40. 103185710 人静脉注射免疫球蛋白中活化凝血因子Ⅺ检测方法
CN
03.07.2013
G01N 21/64 Loading...
G01N 21/64
Loading...
201310041747.7
中国医学科学院输血研究所
马莉
G01N 21/64
Loading...
本发明人静脉注射免疫球蛋白中制品中活化凝血因子XI检测方法，①将IVIG样品与一种经特殊预处理的人乏血小板血浆（PPP）混合；②向反应体系中添加含有磷脂剂的凝血酶特异荧光底物；③添加起始因子启动TGT,该起始因子组分包括一种钙离子源、一种磷脂剂；④优化的反应体系获得提供参数的凝血酶生成曲线；⑤受检样品凝血酶含量达到峰值时所需时间TTP与样品中所含FXIa水平呈负有关。将受检样品TTP与FXIa标准品TTP进行比较，可以间接获得受检样品中FXIa的水平。这种活化凝血因子FXIa的检测方法，适用于人静脉注射丙种球蛋白（IVIG）制品中残留的微量FXIa的检测，及用于体外评估相关制品的致栓性风险。
41. 103184201 虫草素合成酶
CN
03.07.2013
C12N 9/16 Loading...
C12N 9/16
Loading...
201210395708.2
邦泰生物工程（深圳）有限公司
张琦
C12N 9/16
Loading...
本发明披露具有虫草素合成酶活性的多肽，该多肽的特征在于：(a)其序列与说明书中所附的序列SEQ ID NO：2的1到273位氨基酸具有至少60％的氨基酸同一性；(b)由多核苷酸编码的多肽，所述多核苷酸之序列与SEQ ID NO：1的1到822位核苷酸具有至少60％的同一性，优选地100个核苷酸上至少80％或90％相同，更优选地在200个核苷酸上至少90％相同；(c)该多肽能用于合成虫草素。
42. 103114110 利用固定化酶合成胆红素的方法
CN
22.05.2013
C12P 17/16 Loading...
C12P 17/16
Loading...
201210395683.6
邦泰生物工程（深圳）有限公司
张琦
C12P 17/16
Loading...
本发明涉及一种胆红素生产方法技术领域。本发明公开利用固定化酶促合成胆红素的方法。该方法包括如下步骤：a)分别克隆血红素加氧酶基因和胆绿素还原酶基因；b)于大肠杆菌中分别表达重组的血红素加氧酶和胆绿素还原酶；c)提取血红素加氧酶的粗提物或其纯酶以及胆绿素还原酶的粗提物或其纯酶；d)固定化血红素加氧酶的粗提物或其纯酶以及胆绿素还原酶的粗提物或其纯酶；e)同时用固定化血红素加氧酶和固定化胆绿素还原酶催化，以血红素和氧气为底物，在氧化型辅酶II辅助下制备胆红素。
43. 103103234 利用固定化酶合成烟酰胺腺嘌呤二核苷酸(NAD)的方法
CN
15.05.2013
C12P 19/32 Loading...
C12P 19/32
Loading...
201210434517.2
邦泰生物工程(深圳)有限公司
张琦
C12P 19/32
Loading...
本发明涉及一种烟酰胺腺嘌呤二核苷酸生产方法技术领域。本发明公开利用固定化酶促合成烟酰胺腺嘌呤二核苷酸的方法。该方法包括如下步骤：a)克隆烟酰胺核苷腺苷酰转移酶(nicotinamide-nucleotide adenylyltransferase)基因；b)于大肠杆菌中表达重组的烟酰胺核苷腺苷酰转移酶；c)提取重组的烟酰胺核苷腺苷酰转移酶的粗提物或其纯酶；d)固定化重组烟酰胺核苷腺苷酰转移酶的粗提物或其纯酶；e)用固定化重组烟酰胺核苷腺苷酰转移酶催化，以烟酰胺核苷酸和三磷酸腺苷二钠(ATP)为底物制备烟酰胺腺嘌呤二核苷酸。
44. 103063593 一种人抗凝血酶-Ⅲ浓缩物中肝素含量的测定方法
CN
24.04.2013
G01N 21/31 Loading...
G01N 21/31
Loading...
201210589290.9
中国医学科学院输血研究所
叶生亮
G01N 21/31
Loading...
本发明公开了一种人抗凝血酶-Ⅲ浓缩物中肝素含量的测定方法，其特征是包括待测样品的处理、标准曲线的制作与样品的测定三个部分。待测样品的处理方法为稀释与加热处理，标准曲线的制作与样品的测定采用微量发色底物法。发明有益效果是：利用微量发色底物法进行测定，具有灵敏度高，操作简单、省时，检测所需试剂用量小等优点；通过60~80℃加热处理待检样品抗凝血酶-Ⅲ浓缩物20~50min，能够灭活待检样品中对结果造成很大影响的抗凝血酶-Ⅲ成分，但不会对肝素的活性产生影响，提高了测定结果的准确性；采用绘制标准曲线计算结果，稳定性、准确性高。
45. 103063592 一种肝素活性的测定方法
CN
24.04.2013
G01N 21/31 Loading...
G01N 21/31
Loading...
201210589118.3
中国医学科学院输血研究所
曹海军
G01N 21/31
Loading...
本发明公开一种肝素活性的测定方法，包括标准品与样品处理，标准曲线制定及样品测定，样品肝素活性含量计算三步；其反应体系及时间：①10～40μl肝素活性浓度为0～0.1IU/ml的标准曲线制定溶液及样品与10～40μl浓度为1IU/ml的抗凝血酶混合，37℃孵育3分钟；②加入10～40μl浓度为10nkat/ml活化的牛凝血因子Ⅹ，混合后37℃孵育1.5分钟；③加入10～40μl浓度为2.5mmol/L发色底物S-2765，混合后37℃孵育3分钟；④加入10～40μl体积浓度为50%的乙酸，混合均匀终止反应；试剂使用微量，检测效率高，测定结果精准度高，更适应于较低肝素活性样品的检测。
46. 103059129 制造人抗凝血酶-III制品的方法
CN
24.04.2013
C07K 14/81 Loading...
C07K 14/81
Loading...
201310030446.4
贵州泰邦生物制品有限公司
胡吉军
C07K 14/81
Loading...
本专利涉及一种制造人抗凝血酶-III制品的方法，以Cohn低温乙醇法分离血浆蛋白工艺的组分Ⅳ沉淀为原料，经过抽提、压滤、肝素亲和层析、超滤、除菌过滤、冻干等工序以及必要的S/D及干热病毒灭活工艺，最终制备出高纯的抗凝血酶-Ⅲ冻干制品。本方法调整工艺尽可能使其中的AT-Ⅲ溶解；经加入适当保护剂以S/D病毒灭活工艺代替巴氏病毒灭活工艺，减少活性损失，缩短制备时间；并且只需一步肝素亲和层析就可得到高纯度的AT-Ⅲ溶液，再经过超滤、冷冻干燥、干热病毒灭活等步骤，最终制品纯度在95%以上，比活在6.5IU/mg以上，高于欧洲药典及美国药典规定限度3.0IU/mg。
47. 103041380 人抗凝血酶制剂干热处理过程中的稳定剂
CN
17.04.2013
A61K 38/57 Loading...
A61K 38/57
Loading...
201210582536.X
中国医学科学院输血研究所
曹海军
A61K 38/57
Loading...
本发明涉及人血浆蛋白制品技术领域，是一种人抗凝血酶制剂干热处理过程中的稳定剂，本发明的稳定剂是指苯丙氨酸或其盐中的一种、赖氨酸或其盐中的一种、酪氨酸或其盐中的一种、天冬氨酸或其盐中的一种用去离子水配制成的稳定剂溶液；实验证明，在人抗凝血酶制剂100℃，30min干热处理过程，含有质量百分浓度为1.0-2.0%苯丙氨酸或其盐中的一种，0.1-0.6%赖氨酸或其盐酸盐，0.6-2.0%酪氨酸或其盐，0.6-2.0%天冬氨酸或其盐中的一种就能有效保护抗凝血酶的活性，并且干热处理后有较好的制剂外观及复溶澄清度。因此，本发明可作为人抗凝血酶制剂干热处理过程中的稳定剂。
48. 103018188 一种检测人蛋白C活性的方法
CN
03.04.2013
G01N 21/31 Loading...
G01N 21/31
Loading...
201210584582.3
中国医学科学院输血研究所
王宗奎
G01N 21/31
Loading...
本发明公开了一种检测人蛋白C活性的方法，用于检测人蛋白Ｃ活性的发色底物的方法，包括：激活和显色:同时进行，所用的样品稀释液为pH7.2-8.4的20-50mM的Tris缓冲液或Hepes缓冲液，从而使稀释后的样品pH在7-8之间，与生理情况下血浆的pH相近，进而保证检测的准确性；加入的人蛋白Ｃ激活剂的浓度为0.05-0.4IU/ml，显色底物的浓度为0.05-2mg/ml，保证人蛋白Ｃ能完全反应；本发明的有益效果是，将传统的检测人血浆PC的发色底物法过程中的两个单独的“激活”和“显色”过程合并为一个“激活和显色”步骤，大大简化了操作步骤，使操作时间降为传统的1/2～2/3,减少造成人为失误的可能性，检测准确性与灵敏度达到传统检测方法要求。
49. 102973526 人抗凝血酶制剂冷冻干燥过程中的保护剂
CN
20.03.2013
A61K 9/19 Loading...
A61K 9/19
Loading...
201210584198.3
贵州泰邦生物制品有限公司
叶生亮
A61K 9/19
Loading...
本发明公开了一种人抗凝血酶制剂冷冻干燥过程保护剂，所述保护剂为蔗糖或氨基酸或其盐，所述氨基酸或其盐为赖氨酸或其盐酸盐，酪氨酸或其盐，天冬氨酸或其盐中的一种。试验表明，在人抗凝血酶制剂冷冻干燥前只要加入质量百分浓度为0.1%-0.8%蔗糖或0.2%-1.0%赖氨酸或其盐酸盐或0.2%-1.0%酪氨酸或其盐或0.2%-1.0%天冬氨酸或其盐，就可以在冷冻干燥过程中有效保护抗凝血酶的活性。
50. 202815624 一种原料血浆袋融浆温度精确在线控制装置
CN
20.03.2013
G05D 23/20 Loading...
G05D 23/20
Loading...
201220268430.8
山东泰邦生物制品有限公司
林锋
G05D 23/20
Loading...
本实用新型公开了一种原料血浆袋融浆温度精确在线控制装置，其包括池体，在池体外侧设置有与池体内融浆用水进行换热的循环保温夹层，循环保温夹层连通进液管与出液管，进液管分别连通冷媒管道与热媒管道，在池体和/或循环保温夹层内设置有温度传感器，温度传感器连接智能温度控制系统，智能温度控制系统控制冷媒管道与热媒管道上阀门的开闭。本实用新型通过对融浆温度的精确控制，保护了血浆中各类生物蛋白（人免疫球蛋白、抗凝血酶Ⅲ及凝血因子Ⅷ、Ⅱ、Ⅶ、Ⅸ、Ⅹ等）的生物学活性，有效降低血浆蛋白在上游工艺中的损失，提高血制品中各类活性生物蛋白收率。
51. 202315485 一种料液过滤装置
CN
11.07.2012
B01D 29/11 Loading...
B01D 29/11
Loading...
201120481067.3
山东泰邦生物制品有限公司
朱孟沼
B01D 29/11
Loading...
本实用新型涉及一种过滤装置，具体为一种用于食品、生物制药、石油和化工领域的料液过滤装置。其目的在于提供一种可以方便清除筛网堆积物的密闭式料液过滤装置。本实用新型的目的是采用下述技术方案实现的：一种料液过滤装置，它包括滤筒和滤筒底板，滤筒和滤筒底板构成密闭空间，滤筒底板上设有进液口，滤筒上端设有出液口，滤筒内设置有锥尖向上无底面的锥形滤网，滤筒底板上的进液口与滤筒内的喷嘴相通，喷嘴深入锥形滤网内。本实用新型的有益效果是：密闭的过滤装置，更符合各个应用领域严格的工艺要求；过滤物不会大量沉积在滤网表面，不需多次拆卸滤筒；缩短工艺时间，操作简便快捷，提高了产品质量。
52. 102295696 Method for preparing coagulation factor VIII, fibrinogen and fibronectin from cryoprecitation
CN
28.12.2011
C07K 14/755 Loading...
C07K 14/755
Loading...
201110234266.9
Shandong Taibang Biologic Products Co., Ltd.
Shi Xiumei
C07K 14/755
Loading...
The invention relates to the field of blood products, in particular to a process method for preparing three kinds of blood products from cryoprecitation, and aims to provide a complete separation and purification process for respectively and sequentially preparing the three kinds of blood products, i.e. a coagulation factor VIII, fibrinogen and fibronectin, from the cryoprecitation. The process method is implemented by the following technical scheme that the process method comprises the preparation steps of cryoprecitation dissolution, gel adsorption, precipitation of the fibrinogen and the fibronectin, two-step ion exchange chromatography and glycin/sodium chloride precipitation and inactivation of virus. The process method has the beneficial effects that the three kinds of useful blood products, i.e. the coagulation factor VIII, the fibrinogen and the fibronectin, can be separated and extracted from the cryoprecitation sequentially; and the utilization rate of blood plasma is greatly improved.
53. 102284057 Method for preparing placenta polypeptide injection
CN
21.12.2011
A61K 38/02 Loading...
A61K 38/02
Loading...
201110209778.X
Guizhou Taibang Biological Products Co., Ltd.
Zhong Zhengxiao
A61K 38/02
Loading...
The invention discloses a method for preparing a placenta polypeptide injection. The method comprises the following steps of: performing virus examination on placentae, and mixing the placentae and physiological saline, and crushing to obtain placenta tissue slurry; preparing dislysate from the placenta tissue slurry further, dialyzing for three times, filtering supernate formed by clarifying the dislysate by a filter cartridge with the bore diameter of between 0.45 and 1.0 micrometer, and performing ultrafiltration by using a membrane of which the molecular weight is between 5,000 and 10,000 Daltons; and after performing the ultrafiltration, sterilizing and filtering ultrafiltrate which is subjected to virus inactivation continuously at the temperature of between 60+/-0.5 DEG C for 10 hours by using the filter cartridge with the bore diameter of 0.22 micrometer, filling and sealing, and detecting leakage. In the method, a low-temperature dialytic process is adopted, and a novel preparation method for ensuring active ingredients of the placenta polypeptide injection and killing and removing pathogenic microorganisms of the placenta polypeptide injection completely is provided, so the prepared placenta polypeptide injection has an obvious curative effect, the safety of the production and use of products is ensured, and the production rate of the products is improved.
54. 102266354 Method for preparing raw materials for preparing placenta polypeptide injection
CN
07.12.2011
A61K 35/50 Loading...
A61K 35/50
Loading...
201110209777.5
Guizhou Taibang Biological Products Co., Ltd.
Zhong Zhengxiao
A61K 35/50
Loading...
The invention discloses a method for preparing raw materials for preparing a placenta polypeptide injection. The method comprises the following steps of: collecting placentae of healthy puerperae, placing 5 milliliters of blood of the corresponding human placentae in a sterile container, sealing and storing at the temperature of below 10 DEG C, ensuring that time from parturition to freezing storage (-20 DEG C) does not exceed 8 hours, performing inspection of epatitis B surface antigen (HBsAg), syphilis, human immunodeficiency virus (HIV1+2) antibodies and hepatitis C virus (HCV) antibodies on test tubes containing the blood of the human placentae one by one, and recording inspection results, and archiving for future examination, wherein the storage temperature of the placentae is below -20 DEG C, the storage period from the parturition of the placentae to the time of putting on production does not exceed 2 years; performing cold chain transportation at the temperature of below -20 DEG C, performing snap check on the virus before medicines are manufactured, and ensuring that the missed check of the medicines is prevented; and ensuring the safety of biochemical products from the source, and keeping the activity of the original ingredients to a maximum degree. By the process for preparing the raw materials, the quality of the medicines meets the requirement of national standard production, and reliable guarantee is provided.
55. 102250240 Method for purifying human immunoglobulin from separated component I+III of blood plasma
CN
23.11.2011
C07K 16/00 Loading...
C07K 16/00
Loading...
201110174857.1
Shandong Taibang Biological Product Co.,Ltd.
Ma Shan
C07K 16/00
Loading...
The invention relates to a method for separating and purifying human immunoglobulin from a component I+III of blood plasma, and aims to provide a high-efficiency method for recovering high-purity human immunoglobulin. According to the technical scheme provided by the invention, the method comprises the following steps of: a, fully dissolving component I+III precipitate; b, precipitating with octylic acid and removing lipid and a part of impurity protein to prepare IgG (Immunoglobulin G); c, purifying through anion exchange column chromatography; and d, collecting flow-through liquid, performing membrane nanofiltration, ultrafiltration and concentration, preparing the human immunoglobulin, sterilizing and packaging. The method has the beneficial effects of capability of being operated at the room temperature, simple and short steps, high yield, low energy consumption and high output and is suitable for mass production; comprehensive utilization of the blood plasma is fully realized; the time of the entire production process is shortened; the cost is reduced; extremely considerable economic benefit can be produced; the safety of a product is guaranteed by using two virus inactivation/elimination methods of different mechanisms; the environmental pollution is avoided; and the method has high economic and social values.
56. 201889108 一种批式吸附用的密闭式凝胶过滤装置
CN
06.07.2011
B01D 29/075 Loading...
B01D 29/075
Loading...
201020605340.4
山东泰邦生物制品有限公司
朱孟沼
B01D 29/075
Loading...
本实用新型公开一种批式吸附用的密闭式凝胶过滤装置，包括密闭式过滤柱、用于搅拌进入过滤柱内料液的磁力搅拌装置，以及用于支撑、旋转过滤柱的支撑旋转装置，所述过滤柱的底端设置有料液入口，所述过滤柱的顶端设置有滤液出口，在过滤柱的内部设置有滤布与用于支撑滤布的筛板。本实用新型可以大大缩短凝胶过滤所需的时间，提高效率，间接提高药品质量，减少生物活性物质的损失；可以实现搅拌操作的自动化、速度可控，从而提高生产工艺的可控性；可以使批式吸附工艺操作实现完全密闭，减少来自环境的污染源对药物质量的影响。
57. 201538749 生物制药用瞬时反应器
CN
04.08.2010
C07K 14/765 Loading...
C07K 14/765
Loading...
200920239479.9
山东泰邦生物制品有限公司
庞广礼
C07K 14/765
Loading...
本实用新型涉及生物制品分离装置技术领域，特别是一种生物制药用瞬时反应器。包括设置有输液管道的储液罐，所述输液管道上设置有耐压夹层反应器。耐压夹层反应器内胆与输液管道密闭连接。外壳上设置有冷媒进口和冷媒出口，通过三通调节阀与夹层冷媒循环泵配合连接。耐压夹层反应器远离储液罐的一端与血浆计量泵、缓冲液计量泵配合连接。使用三通调节阀调节冷媒循环的流量，使反应液瞬间达到规定要求。采用该瞬时反应器提高了反应速度，缩短了反应时间，避免了蛋白质因搅拌剪切力所致的结构改变，降低了劳动强度，节约了操作空间，减少了反应罐的体积，实现了蛋白质的快速分离自动化。
58. 101747432 Method for preparing alpha 1-antitrypsin medicine
CN
23.06.2010
C07K 14/81 Loading...
C07K 14/81
Loading...
200910255836.5
China Biological Products, Inc.
Jian Changyong
C07K 14/81
Loading...
The invention discloses a method for preparing alpha 1-antitrypsin medicine, in particular to a method for purifying alpha 1-antitrypsin medicine from component IV-1 separated from human plasma. The invention comprises the following steps: component IV-1 is dissolved in buffer solution, PEG is added, upper layer clear liquid is extracted after sedimentation, S/D virus inactivation and anion exchange chromatography are conducted to the upper clear liquid to obtain alpha 1-antitrypsin eluent, hyperfiltration and molecular sieve chromatography are conducted to the obtained alpha 1-antitrypsin eluent, effluent liquid in peak activity range is collected, hyperfiltration, concentration and DV20 nano membrane filtration are conducted to the effluent liquid, and the obtained filtered liquid is split-packaged, frozen and dried to obtain alpha 1-antitrypsin finished product. The invention has the advantages that the operation is simple and convenient, the production time is shortened, the efficiency and the yield are improved, the yield is more than or equal to 70 percent, the specific activity is more than or equal to 0.8, the obtained product is high-purity and the purity is more than or equal to 95 percent.
59. 101747434 Chicken pox-herpes zoster human immune globulin and material production method thereof
CN
23.06.2010
C07K 16/08 Loading...
C07K 16/08
Loading...
201010011478.6
China Biological Products, Inc.
Cao Qianggeng
C07K 16/08
Loading...
The invention relates to a biological product medicament and a material preparation method thereof, in particular to chicken pox-herpes zoster human immune globulin and a material production method thereof. The immune globulin obtained by the method has the content more than 98 percent of the content of total proteins; the contents of an Ig G monomer and a dimmer are more than 99 percent; the antibody titer of chicken pox is more than and equal to 100 IU/ml; and the content of the proteins is less than 129 g/L. The invention greatly enhances the product purity, the stability and the safety and effectively reduces the side reaction and the potential untoward effect of patients.
60. 101709085 Polyethylene glycol modified human serum albumin and preparation method thereof
CN
19.05.2010
C07K 14/765 Loading...
C07K 14/765
Loading...
200910229546.3
School of Pharmaceutical Sciences Shandong University
Liu Chunhui
C07K 14/765
Loading...
The invention relates to the biomedical technical field, in particular to polyethylene glycol modified human serum albumin and a preparation method thereof. The polyethylene glycol modified human serum albumin comprises sulfydryl of 34-bit cysteine residues on albumin molecules and N-terminal amino or free amino group combined polyethylene glycol. Modifiers adopted by the fixed-point single modification are respectively polyethylene glycol-maleimide and polyethylene glycol-propionaldehyde; modifiers adopted by the free amino group random modification are respectively polyethylene glycol-succinimide active ester or methoxy-polyethylene glycol activated by cyanuric chloride; and the modification rate of the free amino group on the albumin molecules combined with the polyethylene glycol is 3%-7%. Compared with the natural albumin, the polyethylene glycol modified human serum albumin has the excellent characteristics of prolonged half-life period, slow plasma elimination, and the like and is beneficial to reducing the medication frequency and releasing the rare albumin source.
61. 101450967 High-purity rabies human immunoglobulin and raw material production method thereof
CN
10.06.2009
C07K 16/06 Loading...
C07K 16/06
Loading...
200710114839.8
Shandong Taibang Biologic Products Inc.
Pang Guangli
C07K 16/06
Loading...
The invention relates to a biological product drug and a method for preparing raw materials thereof, in particular to high-purity rabies human immunoglobulin and a method for producing raw materials thereof. The high-purity rabies human immunoglobulin obtained by the method contains high-titer rabies antibody; the purity of the immunoglobulin is over 98 percent; the content of IgG monomer and dimer is more than 99 percent; the titer of the rabies antibody is more than or equal to 150 IU/ml; and the protein content is less than 120 g/L. The immunoglobulin has the advantages that the immunoglobulin can effectively protect patients and reduce the dosage of the product, as well as can alleviate the pain and burden of the patients.
62. 101439047 Technological process for improving stable FVII yield of human prothrombin complexes
CN
27.05.2009
A61K 38/48 Loading...
A61K 38/48
Loading...
200710114703.7
Shandong Taibang Biological Product Co., Ltd.
Liu Xinyan
A61K 38/48
Loading...
The invention relates to the field of bio-pharmaceutical technology, in particular to a technical method for improving stable F VII yield rate of human thrombogen complex. The following procedures are included: freshly freezing blood plasma of a healthy person at a low temperature; removing cryoprecipitate; carrying out clarification filtration; adjusting ionic strength; carrying out gel absorption; carrying out wash and elution; carrying out ultrafiltration; killing S/D virus; carrying out gel absorption; carrying out wash and elution; carrying out ultrafiltration; carrying out aseptic filtration and subpackage; carrying out freeze-drying; and carrying out hot-air sterilization.
63. 101441219 Coronary heart disease and palsy risk diagnosis reagent kit and manufacturing method thereof
CN
27.05.2009
G01N 33/577 Loading...
G01N 33/577
Loading...
200710114702.2
Shandong Taibang Biological Product Co., Ltd.
Lin Dong
G01N 33/577
Loading...
The invention relates to the field of medical biotechnology, in particular to a making method for coronary heart disease and apoplexy risk diagnosis kit. The kit is used for quantitative analysis of Lp-PLA2 level in human plasma or blood serum by enzyme linked immunosorbent assay, so as to prevent heart disease and apoplexy.
64. 201169579 一种人血白蛋白分离用乙醇雾化扩散装置
CN
24.12.2008
C07K 1/14 Loading...
C07K 1/14
Loading...
200820025021.9
山东泰邦生物制品有限公司
刘欣晏
C07K 1/14
Loading...
本实用新型涉及生物制品分离纯化技术领域，特别是一种人血白蛋白分离用乙醇雾化扩散装置。包括密闭的反应罐，顶搅拌，反应罐罐壁上设置有乙醇管道，乙醇管道罐内端固定连接有雾化喷头，罐外端设置有气动隔膜阀、流量计，并最终与乙醇循环泵配合连接。本方案改原乙醇入口为雾化喷头、喷头在反应液的表面，避免了局部乙醇浓度过高导致的蛋白质变性；保证了乙醇与反应物充分接触，降低了乙醇用量；保持了蛋白质天然的生物活性和有效性，确保了临床用药的有效和安全；而且其结构简单、使用灵活、方便，能够有效提高工作效率。
65. 201168214 一种生物制药低温注射用水转换器
CN
24.12.2008
A61J 3/00 Loading...
A61J 3/00
Loading...
200820025022.3
山东泰邦生物制品有限公司
仲立军
A61J 3/00
Loading...
本实用新型涉及一种生物制药低温注射用水转换器，包括带夹套的注射用水储罐，与储水罐连接的注射用水管道，注射用水管道上按照距离注射用水储罐由远及近的顺序依次串联有水冷不锈钢板式换热器和－15℃乙二醇不锈钢板式换热器。结构简单、使用方便，注射用水的降温加快，保证了低温注射用水的开阀即用，满足规模化生产的需要，大大提高了生产效率。而且水冷转换器内的循环水经热交换后温度在30℃以上，软化后进入锅炉，也有效地节约了能源，提高了水资源的综合利用。
66. 201168226 人血白蛋白病毒灭活循环保温控制设备
CN
24.12.2008
A61L 2/04 Loading...
A61L 2/04
Loading...
200820025717.1
山东泰邦生物制品有限公司
刘欣晏
A61L 2/04
Loading...
本实用新型涉及一种人血白蛋白病毒灭活循环保温控制设备。包括三层灭活罐，内层为316L材质的盛放制品的制品罐，中间层为容纳调温循环水的夹层，外层为保温层，三层灭活罐的夹层底部通过管道依次与管道循环泵和温度传感器一配合连接，并与均设置有电磁阀的加热器和降温换热器并联后，通过设置有温度传感器二的管道再与灭活罐的夹层的顶端连接。本方案所述设备，可以快速升温并自动循环保温，保温到规定时间后又能快速降温，自动化程度高，温度控制精度高，不锈钢罐底部设有电子称，可自动称重，计量准确。保障了血液制品的用药安全，降低了劳动强度，提高了技术水平。
67. 1568906 Stainless steel cardiovascular bracket with pharmaceutical coating on surface and preparation method thereof
CN
26.01.2005
A61F 2/06 Loading...
A61F 2/06
Loading...
200410018039.2
Shanghai Rebone Biomaterials Co., Ltd.
Liu Changsheng
A61F 2/06
Loading...
The invention discloses a 316L stainless cardiovascular stent with a hybrid medicament smear layer and its preparation method. The hybrid medicament smear layer consists of non-biodegradation elastomer, anti-hyperplasia agent, and anti-thrombus agent. Wherein, the inner layer is made up of non-biodegradation elastomer and medicaments with anti-hyperplasia effect, and the outer layer is made up of non-biodegradation elastomer and medicaments with anti- thrombus effect. The preparation process of the smear layer is that: firstly prepare the non-biodegradation elastomer, the anti-hyperplasia hybrid medicament smear layer, and the non-biodegradation elastomer smear layer orderly on the surface of the stent, and finally, use plasma technology to initiate grafting anti-thrombus medicament on the surface of the outer layer of non-biodegradation elastomer.
68. 1569270 Method for preparing cardiovascular drug eluting stent
CN
26.01.2005
A61L 27/00 Loading...
A61L 27/00
Loading...
200410018040.5
Shanghai Rebone Biomaterial Co., Ltd.
Liu Changsheng
A61L 27/00
Loading...
A process for preparing cardiovascular stent with a drug coating layer on its surface is disclosed. It includes the steps of: 1. pretreatment for the stent surface by plasma 2. dipping or spraying of the stent surface in routine method by hyperplasia proof drug and coating polymer containing solution The drug coated stent prepared by the present invention can endure long period washing by all kinds of stress and body fluid in the stent transportation and dilation process, with the coating layer not easy to falling off.
69. 1411466 Compound (I), method for extracting it and pharmaceutical composition containing it
CN
16.04.2003
C07J 17/00 Loading...
C07J 17/00
Loading...
01803432.2
Taihe Biopharmaceutical Co. Ltd., Guangdong
Guan Yongyuan
C07J 17/00
Loading...
The present invention relates to the compounds of formula (I), a method for extracting it and a pharmaceutical composition containing it. The said extracting method includes: extracting the corpus radicis and/or radix fibrosa of a ginseng spp.plant--panax ginseng or pseudo-ginseng with industrial alcohol, extracting the total saponins with n-butanol, purified by silica gel column chromatography and inversed phase column chromatography, then obtained the compound (I). The said pharmaceutical composition is used for treating acute ischemia cerebrovascular disorders.

